Duminuco, A.; Bulla, A.; Rosso, R.; Romeo, M.A.; Cambria, D.; La Spina, E.; Ximenes, B.; Giallongo, C.; Tibullo, D.; Romano, A.;
et al. Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience. Vaccines 2025, 13, 111.
https://doi.org/10.3390/vaccines13020111
AMA Style
Duminuco A, Bulla A, Rosso R, Romeo MA, Cambria D, La Spina E, Ximenes B, Giallongo C, Tibullo D, Romano A,
et al. Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience. Vaccines. 2025; 13(2):111.
https://doi.org/10.3390/vaccines13020111
Chicago/Turabian Style
Duminuco, Andrea, Anna Bulla, Rosamaria Rosso, Maria Anna Romeo, Daniela Cambria, Enrico La Spina, Benedetta Ximenes, Cesarina Giallongo, Daniele Tibullo, Alessandra Romano,
and et al. 2025. "Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience" Vaccines 13, no. 2: 111.
https://doi.org/10.3390/vaccines13020111
APA Style
Duminuco, A., Bulla, A., Rosso, R., Romeo, M. A., Cambria, D., La Spina, E., Ximenes, B., Giallongo, C., Tibullo, D., Romano, A., Raimondo, F. D., & Palumbo, G. A.
(2025). Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience. Vaccines, 13(2), 111.
https://doi.org/10.3390/vaccines13020111
